ABBV Stock Recent News
ABBV LATEST HEADLINES
AbbVie NYSE: ABBV spooked the market in early October, but the sell-off is a buying opportunity. The critical takeaway is that only the earnings guidance was altered; the trim was small and offset by the cause.
AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AbbVie (ABBV) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Dividend Kings have a 50+ year track record of increasing dividends, showcasing resilience through economic challenges. I rank Dividend Kings by quality score and highlight undervalued stocks for potential investment. The article provides tables and charts presenting quality scores, key metrics, and fair value estimates.
These dividend stocks are great picks as the fall season gets underway.
ABBV lowers adjusted earnings guidance for 2024 from $10.71-$10.91 per share to $10.67-$10.87 to account for acquisition costs.
AbbVie (ABBV) closed the most recent trading day at $195.45, moving -0.7% from the previous trading session.
AbbVie's acquisition of Cerevel Therapeutics enhances its neuroscience pipeline with promising candidates Emraclidine and Tavapadon, expected to significantly boost revenues post-approval. Emraclidine and Tavapadon show strong clinical trial results, positioning them as potential best-in-class treatments for Schizophrenia and Parkinson's Disease, respectively. AbbVie demonstrates financial strength with rising revenues from Skyrizi and Rinvoq, supporting a bullish long-term investment thesis despite Humira's decline.
The pharmaceutical industry plays a crucial role in most of our everyday lives.
AbbVie presents a strong long-term investment opportunity, driven by its strategic focus on neuroscience and IBD treatments, despite challenges from Humira's decline. Tavapadon and other neuroscience drugs offer substantial growth potential, addressing unmet medical needs in Parkinson's and other neurological conditions. Skyrizi and Rinvoq are rapidly growing, offsetting Humira's revenue decline, and positioning AbbVie to capture significant market share in the expanding IBD market.